enGene to host KOL webinar on high-risk NMIBC treatment decisions and LEGEND trial data

• enGene will host a KOL webinar on Oct. 15, 2026 at 10:00 a.m. ET.
• Agenda includes preclinical data supporting a polidocanol surfactant bladder rinse before intravesical detalimogene for BCG-unresponsive, high-risk NMIBC with CIS.
• Community KOLs David J. Cahn, MD, Suzanne B. Merrill, MD, FACS will discuss real-world treatment decision-making using case studies.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. enGene Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202610130800BIZWIRE_USPR_____20261013_BW024970) on October 13, 2026, and is solely responsible for the information contained therein.